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Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in
chronic lymphocytic leukemia treated with ibrutinib
J Yu1, L Chen1, B Cui, Christina Wu, MY Choi, Y Chen, L Zhang, LZ Rassenti, GF Widhopf II and TJ Kipps
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia
(CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton’s tyrosine kinase (BTK) that can block BCR-
signaling. However, ibrutinib cannot induce complete responses (CR) or durable remissions without continued therapy, suggesting
alternative pathways also contribute to CLL growth/survival that are independent of BCR-signaling. ROR1 is a receptor for Wnt5a,
which can promote activation of Rac1 to enhance CLL-cell proliferation and survival. In this study, we found that CLL cells of
patients treated with ibrutinib had activated Rac1. Moreover, Wnt5a could induce Rac1 activation and enhance proliferation of CLL
cells treated with ibrutinib at concentrations that were effective in completely inhibiting BTK and BCR-signaling. Wnt5a-induced
Rac1 activation could be blocked by cirmtuzumab (UC-961), an anti-ROR1 mAb. We found that treatment with cirmtuzumab and
ibrutinib was significantly more effective than treatment with either agent alone in clearing leukemia cells in vivo. This study
indicates that cirmtuzumab may enhance the activity of ibrutinib in the treatment of patients with CLL or other ROR1+ B-cell
malignancies.
Leukemia (2017) 31, 1333–1339; doi:10.1038/leu.2016.368
INTRODUCTION
CLL cells depend on interactions with cells and soluble factors
present in the tumor microenvironment for proliferation and
survival.1–3 Among the pathways that may support CLL prolifera-
tion and survival in vivo, BCR-signaling plays a prominent role.4
Crosslinking of the BCR leads to phosphorylation of CD79α/β and
Src family kinase LYN, resulting in the recruitment and activation
of the tyrosine kinase Syk, which induces a cascade of down-
stream signaling events, leading to enhanced B-cell survival.4 The
importance of this cascade in CLL biology appears underscored by
the clinical activity of small-molecule inhibitors of intracellular
kinases, which play critical roles in BCR-signaling, such as SYK,
phosphoinositide 3-kinase (PI3K) or Bruton’s tyrosine kinase
(BTK).5–7 Ibrutinib is a small molecule inhibitor of BTK that has
proven highly effective in the treatment of patients with CLL.
However, despite having excellent clinical activity, ibrutinib
generally cannot eradicate the disease or induce durable
responses in the absence of continuous therapy.7,8
The failure of ibrutinib to induce complete responses could be
because of alternative survival-signaling pathways, which are not
blocked by inhibitors of BTK. One such pathway is that induced by
signaling through ROR1, an oncoembryonic antigen expressed on
CLL cells, but not on normal postpartum tissues.9,10 We found that
ROR1 could serve as a receptor for Wnt5a,9 which could induce
non-canonical Wnt-signaling that activates Rho GTPases, such as
Rac1, and enhance leukemia-cell proliferation and survival.11–13
Activation of Rac1 by Wnt5a could be inhibited by an anti-ROR1
mAb, cirmtuzumab, which is a first-in-class humanized mono-
clonal antibody currently undergoing evaluation in clinical trials
for patients with CLL.14
We hypothesized that the effects of ibrutinib on blocking BCR-
signaling might be offset by non-canonical Wnt-signaling via
ROR1. If so, then inhibition of both ROR1- and BCR-signaling might
have an enhanced anti-tumor effect. In this study, we investigated
whether Wnt5a/ROR1 signaling was affected by treatment with
ibrutinib and examined the activity of ibrutinib and cirmtuzumab
on CLL cells in vitro and in vivo.
MATERIALS AND METHODS
Blood samples and animals
Blood samples were collected from CLL patients at the University of
California San Diego Moores Cancer Center who satisfied diagnostic and
immunophenotypic criteria for common B-cell CLL, and who provided
written, informed consent, in compliance with the Declaration of Helsinki
and the Institutional Review Board of the University of California San Diego
(Institutional Review Board approval number 080918). PBMCs were isolated
as described previously.13 All experiments with all mice were carried out in
accordance with the guidelines of the National Institutes of Health for the
care and use of laboratory animals, and University of California San Diego
approved study protocol. All mice were age and sex matched. Details of
assays for BTK-occupancy, calcium flux, Rac1 activation, cell proliferation,
cell cycle and animal work are described in the Supplementary Materials
and Methods Section.
RESULTS
Ibrutinib fails to inhibit Wnt5a-induced Rac1 activation in CLL
We examined the blood mononuclear cells of patients who were
taking ibrutinib at the standard dose of 420 mg per day. Freshly
isolated CLL cells had activated Rac1, which diminished over time
in culture in serum-free media unless provided with exogenous
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Wnt5a (Figures 1a and b), as noted for the CLL cells of patients not
taking ibrutinib.13 Moreover, the CLL cells from ibrutinib-treated
patents were incubated with or without Wnt5a and/or cirmtuzu-
mab. Immunoblot analysis showed that Wnt5a induced Rac1
activation in CLL cells from all patients examined, whereas
treatment with cirmtuzumab inhibited Wnt5a-induced Rac1
activation (Figures 1c and d). These results indicate that therapy
with ibrutinib does not inhibit ROR1-dependent, Wnt5a-induced
Rac1 activation.
We examined whether treatment of CLL cells with ibrutinib
in vitro could inhibit Wnt5a-induced Rac1 activation in CLL. For
this, we incubated CLL cells collected from untreated patients
with ibrutinib at concentrations of 0, 0.25, 0.5 or 1.0 μm for 2 h
and then treated the cells with exogenous Wnt5a for 30 min.
Immunoblot analysis demonstrated that ibrutinib could not block
Wnt5a-induced Rac1 activation, even at ibrutinib concentrations
of 1 μm (Supplementary Figure S1A), which is in large excess of
what is required to achieve 100% occupancy of BTK and inhibition
of BTK activity (Supplementary Figure S1B).15–17 On the other
hand, we noted that ibrutinib at concentrations as low as 0.25 μm
inhibited the calcium flux induced by anti-IgM (Supplementary
Figure S1C),18 without acutely affecting CLL-cell viability (Supple-
mentary Figure S1D).
The peak plasma concentration of ibrutinib in patients treated
with this drug is ~ 0.5 μm, a concentration that can affect 100%
occupancy and inhibition of BTK.19,20 Therefore, ibrutinib was
used at 0.5 μm for subsequent studies. We examined for
Wnt5a-induced Rac1 activation with or without ibrutinib and/or
cirmtuzumab. CLL cells were cultured with ibrutinib, cirmtuzumab
or both ibrutinib and cirmtuzumab for 2 h, and then stimulated
with exogenous Wnt5a for 30 min. For comparison, cells from
the same CLL sample were cultured without Wnt5a in parallel.
Treatment of CLL cells with Wnt5a induced activation of Rac1 to
levels that were significantly higher than that of CLL cells that were
not treated with Wnt5a (Figures 1e and f). Treatment with
cirmtuzumab, but not ibrutinib, could inhibit Wnt5a-induced Rac1
activation in CLL cells (Figures 1e and f). As expected, ibrutinib did
not block the capacity of cirmtuzumab to inhibit Wnt5a-induced
Rac1 activation (Figures 1e and f).
Cirmtuzumab inhibits Wnt5a-enhanced proliferation of CLL cells
treated with ibrutinib
Activation of Rac1-GTPase can enhance proliferation,11,13,21
whereas loss of Rac1 results in impaired hematopoietic-cell
growth.22 We induced proliferation of CLL cells by co-culturing
leukemia cells with HeLa cells expressing CD154 (HeLaCD154) and
recombinant interleukin (IL)-4 and IL-10.13,23 Addition of exogen-
ous Wnt5a to co-cultures of CLL cells with HeLaCD154 cells and
IL-4/10 significantly enhanced the proportion of dividing CLL cells.
Treatment of the CLL cells with cirmtuzumab, but not ibrutinib,
could block Wnt5a-enhanced proliferation in CLL cells (Figure 2a).
The same effects were observed for CLL cells of different patients
(n= 6) (Figure 2b). As expected, co-culturing with HeLa cells in the
presence of IL4/10 and/or Wnt5a could not induce CLL-cell
proliferation (Supplementary Figure S2).
We also performed cell-cycle analysis on permeabilized leukemia
cells using propidium iodide and found that Wnt5a stimulation
significantly enhanced the fraction of CD154-stimulated leukemia
cells in S/G2/M (Figures 2c and d). The capacity of Wnt5a to enhance
the proportion of cells in S/G2/M could be inhibited by treatment
with cirmtuzumab, but not ibrutinib (Figures 2c and d). Collectively,
these data demonstrate that cirmtuzumab could block Wnt5a-
signaling leading to enhanced leukemia-cell proliferation, which was
not affected by treatment with ibrutinib.
Activity of cirmtuzumab and/or ibrutinib in CLL patient-derived
xenografts
We transferred CLL cells into the peritoneal cavity of immunodefi-
cient Rag2− /−γc
− /− mice,24 and examined whether treatment
with ibrutinib and/or cirmtuzumab could deplete CLL cells in vivo.
For this, we injected 1 × 107 viable primary CLL cells in AIM-V
medium into the peritoneal cavity of each mouse. One day later,
the mice were provided no treatment or daily doses of ibrutinib
Figure 1. Cirmtuzumab inhibits Wnt5a-Induced Rac1 activation in ibrutinib-treated CLL cells. (a) Activated Rac1 was measured in the freshly
isolated ibrutinib-treated CLL cells or isolated ibrutinib-treated CLL cells cultured in serum free media without or with exogenous Wnt5a
(200 ng/ml), as indicated on the top of each lane. (b) Activated Rac1 was measured in the freshly isolated ibrutinib-treated CLL cells or isolated
ibrutinib-treated CLL cells cultured in serum free media with or without Wnt5a (200 ng/ml). Mean Rac1 activation observed in four
independent experiments is shown (n= 4). (c) CLL cells were collected from ibrutinib treated patients (n= 4). Activated Rac1 was measured in
CLL cells treated with or without Wnt5a (200 ng/ml) or cirmtuzumab (10 μg/ml), as indicated above each lane of the immunoblot (d) Rac1
activation was measured in CLL cells collected from patients undergoing therapy with ibrutinib, which were treated with Wnt5a (200 ng/ml)
and/or cirmtuzumab (10 μg/ml). The average Rac1 activation observed in five independent experiments is shown (n= 5). (e) Activated Rac1
was measured in CLL cells incubated with or without Wnt5a and treated with cirmtuzumab (10 μg/ml) or ibrutinib (0.5 μm), as indicated on
the top of each lane. (f) Wnt5a-induced activation of Rac1 in CLL cells without treatment or treated with cirmtuzumab and/or ibrutinib. Mean
Rac1 activation observed in five independent experiments is shown (n= 5). The numbers below each lane are ratios of band IOD of activated
versus total GTPase normalized to untreated samples. Data are shown as mean± s.e.m. for each group. **Po0.01; ***Po0.001; ****Po0.0001,
as calculated using one-way ANOVA with Tukey’s multiple comparisons test.
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at 15 mg/kg via oral gavage, and/or a single dose of cirmtuzumab
at 1 mg/kg via i.p. injection. After 7 days, the CLL cells were
harvested via peritoneal lavage and the proportions of CLL cells in
the harvested peritoneal cells were examined by flow cytometry
(Figure 3a). The percentages and total numbers of CLL cells in
peritoneal lavage were significantly lower in mice treated with
cirmtuzumab or ibrutinib than in mice that did not receive any
treatment. However, significantly fewer CLL cells were found in
the peritoneal lavage of mice treated with cirmtuzumab and
ibrutinib than in the peritoneal lavage of mice treated with either
agent alone (Figure 3b).
Cirmtuzumab, but not ibrutinib, inhibits Wnt5a-enhanced Rac1
activation and proliferation of ROR1 × TCL1 leukemia cells
ROR1× TCL1 leukemia cells were isolated from ROR1× TCL1
double-transgenic mice that developed ROR1+ leukemia.10 We
pretreated ROR1× TCL1 leukemia cells with ibrutinib or cirmtuzu-
mab for 2 h and then cultured the cells with or without Wnt5a for
30 min. Similar to our findings with human CLL cells, Wnt5a-
induced Rac1 activation could be inhibited by cirmtuzumab,
but not by ibrutinib (Figures 4a and b). The combination of
cirmtuzumab with ibrutinib also inhibited Wnt5a-induced activa-
tion of Rac1 to levels observed in untreated cells (Figures 4a and b).
However, Wnt5a treatment could not induce activation of Rac1
in the leukemia cells of single-transgenic TCL1 mice, which
develop a leukemia that lacks expression of ROR1 (Supplementary
Figure S3A).10
Again, we induced proliferation of ROR1 × TCL1 leukemia cells
by co-culturing the cells with HeLaCD154 in the presence of
recombinant IL-4/10. Exogenous Wnt5a treatment significantly
enhanced the percentage of numbers of cell divisions (Figure 4c).
As with human CLL cells, Wnt5a and/or IL-4/10 alone could not
induce proliferation of ROR1+ leukemia cells of ROR1×TCL1
transgenic mice (Figure 4c), indicating a dependency on CD154
for this effect. In agreement with earlier studies,13 Wnt5a did not
enhance the proliferation of ROR1-negative TCL1-leukemia cells
co-cultured with HeLaCD154 cells and IL-4/10 (Supplementary
Figure S3B), indicating a dependency on ROR1 for this effect.
Treatment with ibrutinib could not inhibit the capacity of Wnt5a
to enhance the proliferation of CD154-induced ROR1× TCL1
leukemia-cell proliferation. On the other hand, cirmtuzumab
blocked the capacity of Wnt5a to enhance ROR1× TCL1 leukemia
cells proliferation in response to CD154 and IL-4/10 (Figure 4c).
As noted for human CLL cells, cell-cycle analysis on permeabilized
ROR1 × TCL1 leukemia cells using propidium iodide demon-
strated that Wnt5a could increase the fraction of CD154-
stimulated ROR1+ leukemia cells in S/G2/M (Supplementary
Figure S4). Moreover, the capacity of Wnt5a to enhance the
fraction of ROR1+ leukemia cells in S/G2/M could be inhibited by
treatment with cirmtuzumab, but not ibrutinib (Supplementary
Figure S4).
Figure 2. Cirmtuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated CLL Cells. (a) CD154-induced proliferation of CFSE-labeled
CLL cells (n= 6) with or without Wnt5a and treated with cirmtuzumab (10 μg/ml) or ibrutinib (0.5 μm). One representative CLL sample is
shown with the percent of dividing cells. (b) The bars indicate the mean proportions of CLL cells with diminished CFSE fluorescence from each
of six different patients for each culture condition indicated at the bottom. (c) CLL cells were co-cultured on HeLaCD154 in the presence of
IL-4/10 or Wnt5a, and then treated with cirmtuzumab (10 μg/ml) or ibrutinib (0.5 μm) for 4 days, subjected to cell-cycle analysis following
propidium iodide staining. One representative CLL sample is shown. (d) The mean fraction of cells in S/G2/M phase for all 4 patients tested is
presented. Data are shown as mean± s.e.m.; *Po0.05; **Po0.01, as determined by one-way ANOVA with Tukey’s multiple comparisons test.
Cirmtuzumab in combination with ibrutinib
J Yu et al
1335
Leukemia (2017) 1333 – 1339
Treatment of immunodeficient mice engrafted with ROR1× TCL1
leukemia with cirmtuzumab and/or ibrutinib
We examined the capacity of cirmtuzumab and/or ibrutinib to
inhibit ROR1 × TCL1 leukemia cell engraftment in Rag2− /−γc
− /−
mice, which were each engrafted with 2 × 104 ROR1× TCL1
leukemia cells. These mice each received daily ibrutinib at 15, 5,
1.67 mg/kg via gavage, or a single dose of cirmtuzumab at 1, 3 or
10 mg/kg via intravenous injection. After 25 days, the animals
were sacrificed and the spleen of each animal was examined.
Ibrutinib (Supplementary Figure S5A) or cirmtuzumab
(Supplementary Figure S5B) reduced the numbers of splenic
leukemia cells in a dose-dependent manner. We selected the
cirmtuzumab dose of 1 mg/kg and the daily dose of ibrutinib
5 mg/kg for combination studies. While the engrafted mice
treated with cirmtuzumab or ibrutinib alone had significantly
smaller spleens than the engrafted animals that did not receive
any treatment, the mice treated with the combination of
cirmtuzumab and ibrutinib had the greatest reductions in spleen
size (Figure 5a). Furthermore, the mean proportion and number of
leukemia cells in the spleen were significantly lower in mice
treated with cirmtuzumab or ibrutinib compared with engrafted
mice that did not receive treatment (Figures 5b and c). However,
the engrafted animals that were treated with cirmtuzumab and
ibrutinib had significantly lower proportions and numbers of
leukemia cells per spleen than all other groups (Figures 5b and c).
Treatment of immunocompetent mice engrafted with
ROR1× TCL1 leukemia with cirmtuzumab and/or ibrutinib
We examined the capacity of cirmtuzumab and/or ibrutinib
to inhibit engraftment of ROR1 × TCL1 leukemia cells (CD5+
B220lowROR1+) in immunocompetent human-ROR1 transgenic
(ROR1-Tg) mice.10 We injected 2 × 104 ROR1× TCL1 leukemia cells
to ROR1-Tg mice, and administered no treatment, daily doses of
ibrutinib at 5 mg/kg via gavage, or weekly doses of cirmtuzumab
at 10 mg/kg via intravenous injection. After 28 days, the animals
were sacrificed and the spleen of each animal was examined.
While the engrafted mice treated with cirmtuzumab or ibrutinib
alone had significantly smaller spleens than the engrafted animals
that did not receive any treatment, the mice treated with the
combination of cirmtuzumab and ibrutinib had the greatest
reductions in spleen size (Figure 6a). Furthermore, the mean
proportion of splenocytes that were leukemia cells and the
average absolute number of leukemia cells in the spleen were
significantly lower in mice treated with either cirmtuzumab or
ibrutinib than in mice that did not receive any treatment
(Figures 6b and c). However, the engrafted animals that were
treated with cirmtuzumab and ibrutinib had significantly lower
proportions and numbers of leukemia cells per spleen than all
other groups (Figures 6b and c).
Figure 3. Effect of treatment with cirmtuzumab and/or ibrutinib
on CLL patient derived xenografts. (a) CLL cells were injected to
the peritoneal cavity of Rag2− /−γc− /− mice 1 day before treatment.
Peritoneal lavage was collected 7 days after cell injection and subjected
to residual CLL determination by cell counting and flow cytometry
analysis following staining with mAb specific for CD5, CD19 and CD45.
The percentages shown in the top right of each contour plot indicates
the proportion of CLL cells among the cells harvested from mice after
treatment. (b) Each bar in the graph represents the percentage of CLL
cells among harvested cells frommice after treatment, normalized with
respect to the percentage of CLL cells among cells harvested from
mice without treatment, which was to 100%. Data shown are mean±
s.e.m. from 3 different patients with 5 mice in each group; ***Po0.001;
****Po0.0001, as calculated using one-way ANOVA with Tukey’s
multiple comparisons test.
Figure 4. Cirmtuzumab inhibits Wnt5a-enhanced proliferation in ibrutinib-treated ROR1× TCL1 leukemia cells. (a) Activated Rac1 was
measured in ROR1× TCL1 leukemia cells incubated with or without Wnt5a (200 ng/ml) and treated with cirmtuzumab (10 μg/ml) and/or
ibrutinib (0.5 μm), as indicated on the top of each lane. The numbers below each lane are ratios of the band densities of activated versus total
GTPase, normalized to untreated samples. (b) Activation of Rac1 in ROR1× TCL1 leukemia cells treated with Wnt5a with or without
cirmtuzumab (10 μg/ml) and/or ibrutinib (0.5 μm). The average Rac1 activation observed in five independent experiments is shown (n= 5).
(c) CD154-induced proliferation of CFSE-labeled ROR1× TCL1 leukemia cells (n= 5) with or without treatment with Wnt5a (200 ng/ml) and/or
cirmtuzumab (10 μg/ml) or ibrutinib (0.5 μm). The bars indicate the mean proportions of ROR1× TCL1 leukemia cells from each of five different
mice that have diminished CFSE fluorescence for each culture condition, as indicated at the bottom. Data are shown as mean± s.e.m.;
*Po0.05; **Po0.01; ****Po0.0001, as calculated using one-way ANOVA with Tukey’s multiple comparisons test.
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DISCUSSION
In this study, we examined the CLL cells of patients undergoing
treatment with ibrutinib, which is highly effective at inhibiting
BCR-signaling through its capacity to inhibit BTK.25,26 First, we
noted that the CLL cells of patients treated with ibrutinib had
activated Rac1, which diminished over time in culture in serum-
free media unless we supplemented the media with exogenous
Wnt5a. Moreover, we found that Wnt5a could induce CLL to
activate Rac1, as noted in a variety of cell types,27–29 including CLL
cells.13 Subsequent studies showed that Wnt5a could induce Rac1
activation even in CLL cells that were treated with ibrutinib at
supra-physiologic concentrations, which exceeded the levels
required to achieve 100% occupancy and inhibition of BTK and
BCR-signaling. In some respects this is similar to the findings of
Ren and colleagues, who reported that ibrutinib could not inhibit
FcγR-induced Rac1 activation, even though it could inhibit FcγR-
induced calcium signaling and cytokine production.17 However,
the Wnt5a-signaling noted in our study was dependent upon
ROR1, as indicated by the capacity of cirmtuzumab to inhibit
Wnt5a-induced activation of Rac1. We conclude that ibrutinib
cannot block ROR1-dependent, Wnt5a-induced activation of Rac1,
which serves as an intracellular signal transducer that can
influence multiple signaling pathways.
Activated Rac1 might mitigate the effectiveness of anti-cancer
therapy. Prior studies found that activated Rac1 can enhance
resistance of CLL cells to cytotoxic drugs.11 One study found that
activated T cells and fibroblasts could induce CLL cells to activate
Rac1 and acquire resistance to the cytotoxic effects of fludarabine
monophosphate; inhibition of activated Rac1 could restore the
sensitivity of these CLL cells to this drug.11 In another study, Rac1
was found to interact with and enhance the function of Bcl-2,30
which is over-expressed in CLL.31 Another study involving acute
leukemia cells found that treatment with NSC-23766, an inhibitor
of activated Rac1, could enhance the cytotoxicity of Bcl-2
antagonists for leukemia cells.32 Finally loss of p53 in lymphoma
cells has been associated with increased activation of Rac1, which
could be inhibited by NSC-23766 or a dominant-negative form of
Rac1, Rac1N17, leading to a dose-dependent increase in the rate
of spontaneous or drug-induced apoptosis.33 Conceivably the
activated Rac1 observed in CLL cells of patients treated with
ibrutinib provides an ancillary signal, which enhances the survival
of leukemia cells of patients treated with ibrutinib.
Furthermore, Wnt5a-signaling also could promote leukemia-cell
proliferation in patients treated with ibrutinib. The functional
consequences of Wnt5-signaling in part are demonstrated by the
ability of Wnt5a to enhance proliferation induced by CD154, which
can induce CLL proliferation in vitro in the presence of exogenous
IL4/10 or IL-21.13,23,34 Although ibrutinib partially could inhibit
CD154-induced CLL cell proliferation, possibly because of its
capacity to inhibit BCR and BCR-independent pathways,25,26,35 we
found that ibrutinib could not inhibit the capacity of Wnt5a to
enhance CD154-induced CLL proliferation via ROR1-dependent
signaling, which could, however, be blocked by treatment with
cirmtuzumab.
Wnt5a most likely is produced by cells in the CLL microenvir-
onment. However, prior studies found that plasma samples of
patients with CLL also have high levels of Wnt5a relative to those
of healthy adults.13 Wnt5a also might be produced by the CLL cells
Figure 5. Additive inhibitory effect of treatment with cirmtuzumab and ibrutinib in immunodeficient mice engrafted histocompatible ROR1+
leukemia. (a) Representative spleens of Rag2− /−γc− /− mice were shown, which were collected 25 days after receiving an intravenous infusion
of 2 × 104 ROR1× TCL1 leukemia cells. (b) Combination of cirmtuzumab and ibrutinib inhibits engraftment of ROR1 × TCL1 leukemia cells in
Rag2− /−γc− /− mice. Rag2− /−γc− /− mice were engrafted with 2× 104 ROR1× TCL1 leukemia cells and then given single intravenous injection of
1 mg/kg cirmtuzumab on day 1, or daily does 5 mg/kg ibrutinib via oral gavage. Contour plots depicting the fluorescence of lymphocytes
harvested on day 25 post adoptive transfer from representative mice (n= 5) that received treatment, as indicated at the top, after staining the
cells with fluorochrome-conjugated mAb specific for B220 (ordinate) and human ROR1 (abscissa). The percentages in the top right of each
contour plot indicate the proportion of the blood mononuclear cells having CD5+B220lowROR1+ phenotype of the leukemia cells. (c) Total
number of ROR1× TCL1 leukemia cells in spleens of recipient Rag2− /−γc− /− mice 25 days after adoptive transfer of 2 × 104 ROR1× TCL1
leukemia cells that received single injection of 1 mg/kg cirmtuzumab or daily injections of 5 mg/kg ibrutinib. Each symbol represents the
number of leukemia cells found in individual mice. Data are shown as mean± s.e.m. for each group of animals (n= 5); *Po0.05, **Po0.01,
***Po0.001, as calculated using one-way ANOVA with Tukey’s multiple comparisons test.
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themselves, allowing for autocrine activation.36 Indeed, one study
found that CLL cells that express high levels of Wnt5a apparently
have increased motility and chemotactic responses than CLL cells
that express little or no Wnt5a, presumably due to the effects of
Wnt5a-autocrine signaling.36 We also noted in an earlier study that
Wnt5a could enhance the migration of CLL cells toward
chemokine via activation of RhoA.13 However, because BTK plays
a prominent role in CLL signaling via chemokine receptors such as
CXCR4,37 we focused our attention on the capacity of Wnt5a to
activate Rac1, which could enhance proliferation induced by
CD154 via signaling pathways that are relatively independent
of BTK.
Because the Wnt5a-ROR1 signaling pathway appears intact in
CLL cells treated with ibrutinib, we examined for additive, if not
synergistic, effects of treatment with ibrutinib and cirmtuzumab.
For mice engrafted with histocompatible ROR1+ leukemia, or
human CLL xenografts, we found that treatment with both
cirmtuzumab and ibrutinib was significantly more effective than
treatment with either agent alone in clearing leukemia cells
in vivo. This study indicates that cirmtuzumab may enhance the
activity of ibrutinib in the treatment of patients with CLL or other
ROR1+ B-cell malignancies.
Combination therapies are often more effective in treating
patients with cancer.38 Investigations are ongoing to evaluate the
activity of ibrutinib in combination with other drugs, such as
venetoclax or anti-CD20 mAbs.39,40 However, other agents that
target signaling pathways that are relatively independent of those
influenced by BCR-signaling also could make excellent candidates
for use in combination with ibrutinib. Because cirmtuzumab
and ibrutinib target independent signaling pathways, they have
apparent synergistic effects in clearing leukemia cells from our
mouse models. By targeting more than one signaling pathway
leading to leukemia-cell growth/survival, combined therapy with
cirmtuzumab and ibrutinib also could potentially mitigate the risk
of acquiring resistance to inhibitors of BTK, as sometimes occurs in
patients who receive ibrutinib monotherapy.41
Taken together, from the perspective of therapeutic efficacy
and drug resistance, our preclinical observations provide a
rationale for the combination therapy with cirmtuzumab with
ibrutinib, or other inhibitors of BTK such as acalabrutinib,42,43 for
patients with CLL or other B-cell malignancies that express ROR1.
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Figure 6. Additive inhibitory effect of treatment with cirmtuzumab and ibrutinib in immunocompetent mice engrafted histocompatible
ROR1+ leukemia. (a) Representative spleens of ROR1-Tg mice were shown, which were collected 25 days after receiving an intravenous
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cells in ROR1-Tg mice. ROR1-Tg mice were engrafted with 2 × 104 ROR1× TCL1 leukemia cells and then given weekly intravenous injection of
10 mg/kg cirmtuzumab or daily does 5 mg/kg ibrutinib via oral gavage. Contour plots depicting the fluorescence of lymphocytes harvested
25 days after adoptive transfer of representative mice (n= 6) that received treatment, as indicated at the top, after staining the cells with
fluorochrome-conjugated mAb specific for B220 (abscissa) and human ROR1 (ordinate). The percentages in the top right of each contour plot
indicate the proportion of the blood mononuclear cells having CD5+B220lowROR1+ phenotype of the leukemia cells. (c) Total number of
ROR1× TCL1 leukemia cells in spleens of recipient ROR1-Tg mice 28 days after adoptive transfer of 2 × 104 ROR1× TCL1 leukemia cells that
received weekly injection of 10 mg/kg cirmtuzumab and/or daily doses of ibrutinib (at 5 mg/kg). Each symbol represents the number of
leukemia cells found in individual mice. Data are shown as mean± s.e.m. for each group of animals (n= 6); *Po0.05, **Po0.01, as calculated
using one-way ANOVA with Tukey’s multiple comparisons test.
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